{"result": "(\"entity\"<|>LIRAGLUTIDA<|>ORGANIZATION<|>Liraglutida is a medication used for weight loss that has shown significant efficacy in clinical studies, improving weight loss outcomes compared to placebo.)\n##\n(\"entity\"<|>ORLISTAT<|>ORGANIZATION<|>Orlistat is a weight loss medication that has been compared to liraglutida, noted for having less effect on body weight.)\n##\n(\"entity\"<|>CETILISTAT<|>ORGANIZATION<|>Cetilistat is a drug similar to orlistat, approved only in Japan, that inhibits gastric and pancreatic lipases for weight loss.)\n##\n(\"entity\"<|>TESOFENSINA<|>ORGANIZATION<|>Tesofensina is a drug that inhibits the reuptake of norepinephrine, dopamine, and serotonin, used in the treatment of Parkinson's disease and weight loss.)\n##\n(\"entity\"<|>BELORANIF<|>ORGANIZATION<|>Beloranif is a drug that inhibits MetAP2, reducing fat biosynthesis and promoting fat oxidation, showing promise in weight loss studies.)\n##\n(\"entity\"<|>LEADER STUDY<|>EVENT<|>The LEADER study is a long-term clinical trial that provided data on the cardiovascular safety of liraglutida in patients with diabetes.)\n##\n(\"entity\"<|>SCALE STUDY<|>EVENT<|>The SCALE study focuses on obesity and prediabetes, analyzing the effectiveness of liraglutida in weight loss.)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>ORLISTAT<|>Liraglutida is compared to orlistat in terms of weight loss effectiveness, with liraglutida showing superior results.<|>8)\n##\n(\"relationship\"<|>CETILISTAT<|>ORLISTAT<|>Cetilistat is a drug similar to orlistat, both of which are used for weight loss by inhibiting lipases.<|>7)\n##\n(\"relationship\"<|>TESOFENSINA<|>LIRAGLUTIDA<|>Tesofensina is mentioned in the context of weight loss treatments alongside liraglutida, indicating a relationship in their use for obesity.<|>5)\n##\n(\"relationship\"<|>BELORANIF<|>LIRAGLUTIDA<|>Beloranif is discussed in relation to liraglutida as a potential weight loss drug, showing a connection in their therapeutic goals.<|>5)\n##\n(\"relationship\"<|>LEADER STUDY<|>LIRAGLUTIDA<|>The LEADER study provides evidence on the safety and efficacy of liraglutida, establishing a direct relationship between the drug and the study findings.<|>9)\n##\n(\"relationship\"<|>SCALE STUDY<|>LIRAGLUTIDA<|>The SCALE study evaluates the effectiveness of liraglutida in weight loss, indicating a strong relationship between the drug and the study's focus.<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , siendo orlistat el que menos efecto tiene\n                                                                       sobre el peso corporal (figura 2).\nlos estudios anteriores, supuso además una disminu-\nción paralela del número de apneas de estos sujetos29.                 4.   Futuro de los tratamientos para\n   En conjunto, liraglutida presenta una OR de 5,54 (IC                     la obesidad\n95%, 4,16-7,78) de probabilidades de que los sujetos\nen tratamiento pierdan ≥ 5% del peso corporal frente a                    Algunos fármacos se han ensayado con éxito para el\nplacebo.                                                               tratamiento de la obesidad, como cetilistat, un inhibi-\n   Efectos secundarios y seguridad de liraglutida:                Los  dor de las lipasas gástrica y pancreática, similar al orlis-\nefectos secundarios más comunes fueron las náuseas                     tat, pero con menos efectos secundarios y, por tanto,\n(15-30% sujetos) y en menor proporción los vómitos                     mejor tolerancia. Cetilistat solo está aprobado en Ja-\n(2-10%) como consecuencia de las acciones del fárma-                   pón (Oblean®, Cetisum® 32.     )\nco a nivel central, pero, seguramente también debidos                     Tesofensina es un inhibidor de la recaptación de no-\nal enlentecimiento gástrico. Los efectos fueron meno-                  radrenalina, dopamina y serotonina, que se emplea\nres después de 4 semanas y aún se pueden minimizar                     como fármaco en el tratamiento del Parkinson, aunque\nsi la escalada de dosis es mucho más paulatina. No hay                 a dosis elevadas. Un único ensayo en fase II publicado\notros efectos secundarios centrales a destacar, por lo                 en 2008, demostró que la dosis de 0,5 mg durante\nque la tolerancia final es buena, siendo la tasa de se-                24 semanas produjo una disminución del 9% del peso\nguimiento de los estudios muy elevada (un 72% de                       corporal, mayor que placebo, con escasa pérdida de\npermanencia, como promedio). La administración del                     seguimiento de pacientes (21%); sin embargo, su de-\nfármaco por vía subcutánea no representó ningún pro-                   sarrollo clínico se ha quedado estancado. Los efectos\nblema de adherencia para los pacientes.                                secundarios más importantes son los derivados de su\n   Liraglutida mejora también las cifras de presión arte-              acción central: sequedad de mucosas, estreñimiento,\nrial y tiene acciones positivas sobre otros marcadores                 insomnio, intranquilidad33.\nde riesgo cardiovascular. Aunque se ha descrito un in-                    Beloranif es un fármaco inhibidor de la metionina\ncremento de 2-4 latidos/min, este efecto no parece                     aminopeptidasa-2 (MetAP2), que reduce la biosíntesis\nque tenga repercusión clínica alguna y parece reflejar                 de grasa, favorece su oxidación y la lipólisis. El trata-\nla acción del fármaco a nivel del receptor situado en el               miento con este fármaco presenta el efecto dual de\nnodo seno-auricular. De hecho, liraglutida (hasta una                  incrementar el metabolismo graso y reducir la sensa-\ndosis de 1,8 mg) ha demostrado ser seguro desde el                     ción de apetito. En estudios clínicos en fase II, beloranif\npunto de vista cardiovascular en las personas con dia-                 produjo una pérdida de peso entre 7-10% superior a\nbetes, tal y como se desprende de los recientes datos                  placebo34; pero, el fallecimiento inesperado de un pa-\nobtenidos a largo plazo con el estudio LEADER30.                       ciente en un ensayo fase III, ha paralizado el desarrollo\n   Uno de los principales retos es identificar a los res-              del fármaco.\npondedores al tratamiento farmacológico. En un suba-                      El tratamiento farmacológico de la obesidad en los\nnálisis del estudio SCALE obesidad y prediabetes, se                   próximos años tendrá un mayor protagonismo en la\nobservó que aquellos que habían perdido                    ≥ 4% de     combinación de moléculas con diferentes mecanismos\npeso a las 16 semanas del inicio del tratamiento con                   de acción para potenciar sus efectos con los menores\nliraglutida 3 mg, conseguían perder ≥ 5% del peso ini-                 efectos secundarios. Se están ensayando asociaciones\ncial al cabo de un año. El 77,3% de los participantes                  de fármacos conocidos como bupropión-zonisamida o\ntratados con el fármaco se encuentran en esta catego-                  de fentermina-lorcaserina. Pero\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}